Under the agreement, JHP Pharma will be responsible for manufacturing and supply of an approved therapy used in cancer patients. JHP Pharma manufactures sterile injectables, biologics, vaccines, ophthalmics
ENB-0040 is a bone targeted enzyme replacement therapy designed to directly target TNSALP to the bone in order to correct the enzyme deficiency, which could result in restoration
Pfizer has already paid $200m to Biocon, as part of the agreement signed between them in October 2010, to get access to the supply of four generic insulin
The company has posted a net income of $20.8m for the fourth quarter of 2010, compared to $47.42m for the same period in 2009. Mylan has earned gross
XIFAXAN is indicated for the treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating. Rifaximin is a gut-selective antibiotic with negligible systemic absorption and broad-spectrum activity
BioSante Pharma is developing LibiGel as a treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. The efficacy trials are being conducted
The success could help make TRO40303 the first treatment to reduce cardiac reperfusion injury which leads to morbidity and mortality myocardial infarction. The study was aimed at assessing
The Enabling the EHR Integration Suite makes it possible to capture detailed specialty data and images from all areas of the cardiovascular service line and beyond and export
Michrom is a provider of liquid chromatography (LC) instrumentation, accessories and consumables for applications in the life science, chemical and applied markets. Bruker Chemical & Applied Markets division
CEQ508 is currently in a Phase 1b/2a clinical development program and is intended for the treatment of Familial Adenomatous Polyposis. CEQ508 comprises attenuated bacteria that are engineered to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.